NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tafalgie Therapeutics

Tafalgie Therapeutics

Private
MarseilleHealthcare & Life Scienceshttps://tafalgie.fr/

Last Round

Series A

Sep 15, 2025

Total Funding Raised

$16.82M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Tafalgie Therapeutics is a biotechnology company that develops non-opioid, pain-relieving peptide therapeutics for the treatment of acute and chronic pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologynon-opioid analgesicspain managementdrug discoverycontract researchCROclinical-stage biotechpeptide therapeuticschronic pain treatmentnon-addictive painkillerneuropathic painbiotech startuppain reliefdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tafalgie Therapeutics Comparables

Compare Tafalgie Therapeutics with similar companies based on industry and business-model similarity.

Tafalgie Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Latigo Biotherapeutics
81%
Akelos Inc.
80%
Algiax Pharmaceuticals
80%

Tafalgie Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 15, 2025
GrantNov 1, 2023

Tafalgie Therapeutics Investors

Notable investors and investment history

Tafalgie Therapeutics investors
InvestorRounds
European Innovation Council FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2026

    Monthly visitors increased 38% MoM, reaching 1.2K.

  • Mar 1, 2026

    Monthly visitors grew 78% MoM.

Tafalgie Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tafalgie Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tafalgie Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMarseille
Employee Range29
Year Founded2020
Last FundingSep 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.